Aktienanalyse zu Medpace Holdings Inc (MEDP)MEDPMedpace Holdings Inc

Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

Medpace Holdings Inc is currently a hold. The stock is trading at $600.65, which is below the analyst price targets ranging from $624 to $692, indicating potential upside. However, the RSI is at 42.51, suggesting the stock is nearing oversold territory but not yet a strong buy signal. Additionally, the recent CEO share sell-off, where he sold 15,978 shares for $10 million, might raise concerns despite his substantial remaining stake of approximately $3.27 billion, indicating confidence in the company.

7 analysts cover MEDP: 1 rate it Buy, 6 Hold and 0 Sell. The average price target is 569.17.